Evaluating Radiotheranostic Targets for Endometrial Cancer
Endometrial cancer is the most common gynecologic malignancy worldwide, and its incidence and mortality rates have increased over the past decade. Although early-stage disease is effectively treated via hysterectomy, a dearth of molecularly targeted therapies means that prognoses are far poorer for those with disseminated or recurrent disease. Herein, we describe the exploration of 3 biomarkers-human epidermal growth factor receptor 2 (HER2), mucin-16 (MUC16), and CD24-as potential radiotheranostic targets for endometrial cancer.
Journal
Journal of Nuclear MedicineAuthors
Funding
ImmunoPET Probes for the Imaging of Lyme DiseasePathologyAutoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancerNovel Reagents for Rapid and Stable Thiol-Based BioconjugationsTargeting DNA Mismatches for Auger Electron Radiotherapy